Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Review uri icon

Overview

abstract

  • In 2004, several investigators reported that somatic mutations in the epidermal growth factor receptor gene were associated with clinical responses to erlotinib and gefitinib in patients with non-small cell lung cancer. Since then, multiple groups have examined the biological properties that such mutations confer as well as the clinical relevance of these mutations in patients with non-small cell lung cancer. Although a tremendous amount of knowledge has been gained in the past 2 years, there remain a number of important epidemiologic, biological, and clinical questions.

publication date

  • December 15, 2006

Research

keywords

  • Carcinoma, Non-Small-Cell Lung
  • ErbB Receptors
  • Lung Neoplasms

Identity

Scopus Document Identifier

  • 33846187218

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-06-0658

PubMed ID

  • 17189394

Additional Document Info

volume

  • 12

issue

  • 24